Compare RGNX & MG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGNX | MG |
|---|---|---|
| Founded | 2008 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.1M | 481.7M |
| IPO Year | 2015 | 2008 |
| Metric | RGNX | MG |
|---|---|---|
| Price | $8.76 | $18.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 501.7K | 127.4K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | $10,393,000.00 | ★ $700,970,000.00 |
| Revenue This Year | $51.21 | $5.47 |
| Revenue Next Year | $19.08 | $3.59 |
| P/E Ratio | ★ N/A | $35.53 |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $6.89 | $7.06 |
| 52 Week High | $16.19 | $19.35 |
| Indicator | RGNX | MG |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 82.53 |
| Support Level | $8.68 | $13.75 |
| Resistance Level | $9.29 | N/A |
| Average True Range (ATR) | 0.48 | 0.60 |
| MACD | 0.02 | 0.21 |
| Stochastic Oscillator | 28.57 | 88.07 |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.